EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

European Treatment and Outcome Study (EUTOS) Score for Chronic Myeloid Leukemia Still Requires More Confirmation

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy

(2011) Deborah L. White et al.   Current Hematologic Malignancy Reports

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY